Supplemental Figure 1: Life table analysis of the progression of diabetes in PTP participants. The dark solid line indicates the progression of diabetes in all PTP participants. The subjects followed long term (both progressors and non-progressors) were in this cohort. The solid dark and gray lines show the rates of progression to diabetes among PTP participants from the high risk group who were identified as having an abn OGTT and, on the second visit, returned with abnOGTT (gray), or a normal OGTT (black dashed). Those who returned with a diabetic OGTT are not shown. The subjects in these cohorts had a significantly higher rate of development of diabetes compared to all PTP participants (log rank test, p<0.001).

Supplemental Figures 2A, B, C: Insulin secretory responses during OGTTs. The insulin

secretory responses during OGTTs are shown for the first visit when an abn OGTT was found

(black line) and for the 2nd visit (red line) when the subjects had a normal (A), abnormal (B), or

diabetic (C) OGTT.

# Supplemental Figure 1

Supplemental Figure 2A

Black=1st visit, Red=2nd visit

Supplemental Figure 2B

Black=1st visit, Red=2nd visit

Supplemental Figure 2C

Black=1st visit, Red=2nd visit

Type 1 Diabetes TrialNet Pathway to Prevention Study Group

<u>Steering Committee</u>: Jay S. Skyler (University of Miami Diabetes Research Institute), Chairman; Mark Anderson (University of California San Francisco), Katarzyna Bourcier (NIAID), Dorothy Becker (University of Pittsburgh), Penelope Bingley (University of Bristol), Janice Blum (Indiana University), Emanuele Bosi (San Raffaele Hospital), Jane Buckner (Benaroya Research Institute), Michael Clare-Salzler (University of Florida), Peter Colman (Walter and Eliza Hall Institute of Medical Research), Linda DiMeglio (Indiana University), C. Garrison Fathman (Stanford University), Stephen Gitelman (University of California San Francisco), Robin Goland (Columbia University), Peter Gottlieb (University of Colorado Barbara Davis Center for Childhood Diabetes), Gilman Grave (NICHD), Carla Greenbaum (Benaroya Research Institute), Bernard Hering (University of Minnesota), Kevan Herold (Yale University), Richard Insel (Juvenile Diabetes Research Foundation), Jeffrey P. Krischer (University of South Florida), Jennifer Marks (University of Miami Diabetes Research Institute), Antoinette Moran (University of Minnesota), Jerry P. Palmer (University of Washington), Mark Peakman (Guy's, King's, and St. Thomas' School of Medicine), Alberto Pugliese (University of Miami Diabetes Research Institute), Philip Raskin (University of Texas Southwestern Medical School), Maria Grazia Roncarolo (San Raffaele Scientific Institute), William Russell (Vanderbilt University), Desmond Schatz (University of Florida), Robert Sherwin (Yale University), Mark Siegelman (University of Texas Southwestern Medical School), Olli Simell (Hospital District of Southwest Finland), Lisa Spain (NIDDK), Andrea Steck (University of Colorado Barbara Davis Center for Childhood Diabetes), James Thomas (Vanderbilt University), Massimo Trucco (University of Pittsburgh), John Wentworth (Walter and Eliza Hall Institute of Medical Research), Diane Wherrett (University of Toronto), Darrell M. Wilson (Stanford University), William Winter (University of Florida), Judith Fradkin (NIDDK, ex-officio), Ellen Leschek (NIDDK, ex-officio).

The consortium members performed the oral glucose tolerance tests, provided samples for monitoring at-risk subjects, and obtained clinical data.